Alembic Share Price

NSE
115.72
-3.70 (3.42%)
ALEMBICLTD • 13 Jun, 2025 | 03:29 PM
BUY

1Y Annualised Return

14.88%

3Y Annualised Return

21.88%

5Y Annualised Return

9.11%

The current prices are delayed, login or Open Demat Account for live prices.

Alembic SIP Return Calculator

Over the past

1 year
3 years
5 years

Total Investment of ₹65,00,000

Would have become ₹70,10,358 (+7.85%)

Daily SIP of 25,000 would have become 70,10,358 in 1 year with a gain of 5,10,358 (+7.85%)

Alembic Stock Performance
Today’s Low - High
114.52
116.99
114.52
116.99
52 Week Low - High
85.46
169.00
85.46
169.00

Open

116.99

Prev. Close

119.42

Total Traded Value

10.69 Cr

View details of Market Depth
Alembic Fundamental

Market Cap (in crs)

2,969.94

Face Value

2

Turnover (in lacs)

1,069.50

Key Metrics
Qtr Change %
31.56% Fall from 52W High
24.9
Dividend yield 1yr %
High in industry
2.1

Alembic Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Alembic Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
60.27 Cr
57.92 Cr
52.91 Cr
50.78 Cr
49.04 Cr

Alembic Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
296.78 Cr
212.26 Cr
191.51 Cr
167.4 Cr
83.79 Cr
167.33 Cr

Alembic Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
23.75 Cr
26.09 Cr
77.31 Cr
17.42 Cr
21.29 Cr

Alembic Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
144.57 Cr
92.87 Cr
80.62 Cr
86.19 Cr
13.84 Cr
93.03 Cr
Alembic Result Highlights
  • Alembic Ltd reported a 18.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 30.4%.

  • Its expenses for the quarter were down by 23.0% QoQ and up 5.3% YoY.

  • The net profit increased 10.3% QoQ and increased 49.5% YoY.

  • The earnings per share (EPS) of Alembic Ltd stood at 2.8 during Q4FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Alembic shareholding Pattern

Promoter
70.9%
Foreign Institutions
1.6%
Domestic Institutions
0.1%
Public
27.4%
Promoter
70.9%
Foreign Institutions
1.8%
Public
27.3%
Promoter
70.9%
Foreign Institutions
2%
Domestic Institutions
0.1%
Public
27.1%
Promoter
70.9%
Foreign Institutions
1.4%
Domestic Institutions
0.1%
Public
27.6%
Promoter
70.9%
Foreign Institutions
1.1%
Public
28%
Promoter
70.9%
Foreign Institutions
0.9%
Public
28.2%

Alembic Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
115.72
Current Price
Bullish Moving Averages
15
Bearish Moving Averages
1
5Day EMA
115.60
10Day EMA
114.10
12Day EMA
113.60
20Day EMA
111.90
26Day EMA
110.80
50Day EMA
108.40
100Day EMA
109.80
200Day EMA
112.90
5Day SMA
115.30
10Day SMA
113.40
20Day SMA
112.40
30Day SMA
109.10
50Day SMA
106.20
100Day SMA
105.20
150Day SMA
114.60
200Day SMA
121.40
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
395938 Rs
1049517 Rs
Week Rs
616713 Rs
1873808 Rs
Month Rs
346464 Rs
904404 Rs
Resistance & Support
115.72
Pivot
Resistance
First Resistance
116.93
Second Resistance
118.19
Third Resistance
119.40
Support
First Support
114.46
Second support
113.25
Third Support
111.99
Relative Strength Index
61.20
Money Flow Index
77.23
MACD
2.82
MACD Signal
2.50
Average True Range
3.68
Average Directional Index
30.12
Rate of Change (21)
8.52
Rate of Change (125)
-22.87

Alembic Latest News

03 JUN 2025 | Tuesday

Alembic Ltd - 506235 - Announcement under Regulation 30 (LODR)-Newspaper Publication

19 MAY 2025 | Monday

Alembic Ltd - 506235 - Compliances-Reg.24(A)-Annual Secretarial Compliance

16 MAY 2025 | Friday

Alembic Ltd - 506235 - Announcement under Regulation 30 (LODR)-Newspaper Publication

View More

Alembic Company background

Founded in: 1907
Managing director: Malika C Amin
Alembic Limited is one of the Indias most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. The Company operates primarily in three lines of business, manufacture of Bulk Drugs, Real Estate and Power Generation through Windmills and Cogen Power Plant which is presently used for captive consumption for the operation of the Bulk Drugs Manufacturing plant at Vadodara. The Company is dealing in Active Pharmaceutical Ingredient (API) Business and Real Estate Business.The company manufacture pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. It works manufacturing facilities at Vadodara in Gujarat and Solan in Himachal Pradesh.Alembic Limited was incorporated in year 1907 with the name Alembic Chemical Works Company Limited in Vadodara to manufacture tinctures and alcohol. They started to manufacture cough syrup, vitamins, tonics and sulphur durgs in 1940. In 1961, they inaugurated the Pencillin Palnt. In 1968, they started to manufacture Streptomycin.In the 1971, they manufactured Erythromycin using expertise from Eli Lilly, USA and in the year 1972, they launched Althrocin, a brand of Erythromycin. In year 1997, Althrocin become top selling brand in India. In the year 2001, they started to manufacture Cephalosporin C. In June 2001, the company formed a wholly owned subsidiary company named Alembic Europe Pvt Ltd in UK.In the year 2005, the company has launched ZERO, a new generation, no calories, Sucralose Based Sugar Substitute which gave entry for the company into the highgrowth lifestyle OTC product segment. In May 2005, the generic alliances and API division were merged to form an independent SBU.The company has set up a formulation manufacturing facility at Baddi in Himachal Pradesh with a production capacity 900 million tablets and 600 million liquid oral bottles annually. During the year 200506, the company has increased the installed capacity of Tablets Capsules and Oral Preparation Ointments by 595 Million Nos and 720 MT respectively.During the year 200506, the company acquired API Plant at Karakhadi in Vadodara. In the year 2007, the company acquired the NonOncology Business of Dabur Pharma Ltd. Also in the same year, they entered into a licensing agreement for its Novel Drug Delivery Platform for Keppra XR with UCB Belgium. During the year 200708, the company acquired the API manufacturing facility of Nirayu Pvt Ltd at Panelav near Vododara.The Company formed a wholly owned subsidiary viz. Alembic Global Holding SA in Neuchatel, Switzerland in 2009. The Pharmaceutical Undertaking of the Company demerged and the same got transferred to Alembic Pharmaceuticals Limited with effect from Appointed date i.e. 1st April, 2010. The maiden real estate project Samsara was completed in 2014. The Company launched second real estate project, VEDA in 201516. It further launched two APIs in 2017. During year 201718, Alembic City Limited (formerly known as Alembic Exports Limited) became whollyowned subsidiary of the Company.During 201819, the Composite Scheme of Arrangement comprising of transfer and vesting of the Identified Real Estate Undertaking of Alembic Limited (the Company / the First Demerged Company) into Shreno Limited (the First Transferee Company/ the Second Demerged Company) and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited (the Second Transferee Company) and their respective shareholders with effect from the Appointed Date i.e. 1st November, 2018 was sanctioned by the Honble National Company Law Tribunal, Ahmedabad Bench (NCLT) vide its order dated 26th July, 2019. Accordingly, Scheme was made effective from 26th July, 2019.The Company launched a residential project VEDA II during 2020.

As of 13 Jun, 2025, ALEMBICLTD share price is ₹115.7. The stock opened at ₹117 and had closed at ₹119.4 the previous day. During today’s trading session, ALEMBICLTD share price moved between ₹114.52 and ₹116.99, with an average price for the day of ₹115.00. Over the last 52 weeks, the stock has recorded a low of ₹85.46 and a high of ₹169.00. In terms of performance, ALEMBICLTD share price has declined by 21.6% over the past six months and has increased by 14.88% over the last year.

Read More

Alembic FAQs

Alembic share price is ₹115.72 in NSE and ₹115.65 in BSE as on 13/6/2025.

Alembic share price in the past 1-year return was 11.26. The Alembic share hit a 1-year low of Rs. 85.46 and a 1-year high of Rs. 169.

The market cap of Alembic is Rs. 2969.94 Cr. as of 13/6/2025.

The PE ratios of Alembic is 20.93 as of 13/6/2025.

The PB ratios of Alembic is 3.48 as of 13/6/2025

You can easily buy Alembic shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Alembic stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

Open Demat Account
+91 -